Document Detail


Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia.
MedLine Citation:
PMID:  2196353     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To test the hypothesis that alternate-day administration of furosemide will result in a sustained improvement in pulmonary function without causing alterations in electrolyte or mineral homeostasis, we conducted a randomized, double-blind, placebo-controlled study of 11 hospitalized, oxygen-dependent, spontaneously breathing infants with chronic bronchopulmonary dysplasia. Infants were randomly selected to receive either furosemide, 4 mg/kg in two divided doses on alternate days orally, or placebo for 8 days, followed by crossover to the alternate-therapy for an additional 8-day period. The two study periods were separated by a 48-hour washout period. Dynamic compliance, total pulmonary resistance, the concentration of electrolytes in serum, and the concentrations of calcium and creatinine in urine were measured on nontreatment days. Alternate-day furosemide therapy increased dynamic lung compliance by 76 +/- 112% and decreased total pulmonary resistance by 20 +/- 39%, compared with placebo (both variables p = 0.032). Alternate-day furosemide therapy did not result in increased urine output, electrolyte abnormalities, or increased urinary calcium excretion. We conclude that this simplified treatment regimen may be useful in the management of infants with chronic bronchopulmonary dysplasia. The results support our previous speculation that furosemide improves pulmonary function by mechanisms unrelated to its diuretic properties.
Authors:
M G Rush; B Engelhardt; R A Parker; T A Hazinski
Related Documents :
10516393 - Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: ef...
12200893 - Role of oxidant injury in the pathogenesis of neonatal lung disease.
9022273 - Mesh-sided cots--yet another potentially dangerous infant sleeping environment.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of pediatrics     Volume:  117     ISSN:  0022-3476     ISO Abbreviation:  J. Pediatr.     Publication Date:  1990 Jul 
Date Detail:
Created Date:  1990-08-17     Completed Date:  1990-08-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0375410     Medline TA:  J Pediatr     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  112-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Airway Resistance / drug effects
Bronchopulmonary Dysplasia / blood,  drug therapy*,  urine
Calcium / urine
Chronic Disease
Clinical Trials as Topic
Double-Blind Method
Esophagus / physiology
Furosemide / administration & dosage,  therapeutic use*
Humans
Infant
Infant, Newborn
Lung Compliance / drug effects
Oxygen / blood
Placebos
Pressure
Pulmonary Ventilation / drug effects
Random Allocation
Respiratory Mechanics / drug effects
Tidal Volume / drug effects
Grant Support
ID/Acronym/Agency:
HL07256/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Placebos; 54-31-9/Furosemide; 7440-70-2/Calcium; 7782-44-7/Oxygen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Natural killer cells in cutaneous malignant melanoma.
Next Document:  Frequent handling in the neonatal intensive care unit and intraventricular hemorrhage.